Condition Header Background

What are PCP and Hallucinogen Use Disorders?

LISTEN TO THIS ARTICLE:

Although phencyclidine and other hallucinogens make up two separate substance use categories, they are frequently studied and discussed together and are often all grouped together under the term “hallucinogens”. In fact, across the two disorders, there are at least four distinct genres of substances (phencyclidines, phenylalkylamines, indoleamines, and ergolines), not to mention several outliers. The common thread across all these substances is that they alter users’ perceptions of reality in several ways.

PCP

Using phencyclidine (‘PCP’, ‘angel dust’) causes aggression and erratic behavior. Users have reduced judgment, and they are frequently confrontational and dangerous. They tend to appear visibly agitated and tense. They also have an altered gait, speech pattern changes, and decreased sensitivity to pain. Chronic phencyclidine or ketamine (‘special K’) use can lead to persistent psychotic states lasting days or weeks beyond the last dose of the drug. These appear very similar to an exacerbation of Schizophrenia. Patients have hallucinations, delusional and disorganized thoughts, separation from reality, agitation, reduced speech, emotional changes, impaired motivation, and social withdrawal. Long term phencyclidine use can also cause speech and cognitive difficulties, depression, anxiety, and suicidality.

MDMA

MDMA (3,4-methylenedioxymethamphetamine, ‘ecstasy’ or ‘molly’) originally developed a reputation as a “club drug”, first seeing frequent use at raves (large, overnight dance parties). It acts not only as a stimulant, but also makes users more empathic and emotionally open. Users experience increased energy, sexual arousal, euphoria, altered senses, and, most classically, increased sensitivity and intimacy with others. MDMA’s other immediate effects are similar to those of amphetamines (to which MDMA is closely related), such as restlessness, muscle tension, dry mouth, teeth grinding, increased heart rate and blood pressure, and high body temperature. Higher doses lead to hallucinations, agitation, anxiety, temporary psychosis, and disorganized and bizarre behavior. A ‘hangover’ period follows in the next 24-48 hours characterized by depression, decreased energy, and lack of concentration.

Chronic MDMA use damages serotonin-releasing cells in the brain, reducing both their numbers and their activity. Brain wave activity in these patients appears similar to that of dementia patients. Patients suffer significant cognitive problems (impaired memory, organization, and problem-solving), and the severity is directly proportional to the amount of MDMA that was used. Patients also deal with long lasting mood and behavioral changes, such as treatment-resistant depression, panic disorder, and impulsivity. They can also experience flashbacks characterized by paranoia, hallucinations, and psychosis.

Hallucinogens

Hallucinogens other than phencyclidine and MDMA manipulate serotonin levels to create auditory, visual, and tactile hallucinations. User’s senses intensify, and they experience changes in perception of the passage of time. The different compounds can bring about emotional reactions, agitation, relaxation, and even metaphysical experiences. The effects of LSD (lysergic acid diethylamide, ‘acid’), psilocybin (‘magic mushrooms’, ‘shrooms’), and peyote cactus take up to 1.5 hours to begin and can last up to 12 hours. Those of Salvia divinorum and DMT (dimethyltryptamine) start within minutes and last up to an hour.

Long term users of these drugs (though most evidence concerns LSD specifically) can develop two different disorders: chronic psychosis and Hallucinogen Persisting Perception Disorder (HPPD). Chronic psychosis mimics schizophrenia and includes paranoia, hallucinations, disorganized thought patterns, and mood issues. HPPD occurs long after the last drug use and consists of episodes (formerly referred to as ‘flashbacks’) of perceptual changes and hallucinations similar to those experienced when the drug is taken.

FIND A PROVIDER

Types of Substance Use Disorders

Wondering about a possible disorder but not sure? Let’s explore your symptoms.

IDENTIFY YOUR SYMPTOMS
References
  1. NIDA. 2015. Hallucinogens and Dissociative Drugs: Brief Description. Available at https://www.drugabuse.gov/publications/research-reports/hallucinogens-dissociative-drugs/director. Accessed 12/8/16. [Citation is in paragraph 1]
  2. Wu, L. T., Ringwalt, C. L., Mannelli, P., & Patkar, A. A. (2008). Hallucinogen use disorders among adult users of MDMA and other hallucinogens. American Journal on Addictions, 17(5), 354-363. [Citation is on p.1, section Background, paragraph 1]
  3. American Psychiatric Association. (2013). Substance Use Disorders. In Diagnostic and statistical manual of mental disorders (5th ed.) [Citation is in section Phencyclidine Use Disorder, Diagnostic Features, paragraph 1]
  4. American Psychiatric Association. (2013). Substance Use Disorders. In Diagnostic and statistical manual of mental disorders (5th ed.) [Citation is in section Other Hallucinogen Use Disorder, Diagnostic Features, paragraph 1]
  5. NIDA. 2014. Hallucinogen: Brief Description. Available at https://www.drugabuse.gov/drugs-abuse/hallucinogens. Accessed 12/8/16. [Citation is in paragraph 1]
  6. American Psychiatric Association. (2013). Substance Use Disorders. In Diagnostic and statistical manual of mental disorders (5th ed.) [Citation is in section Phencyclidine Intoxication, Diagnostic Features, Criterion B]
  7. American Psychiatric Association. (2013). Substance Use Disorders. In Diagnostic and statistical manual of mental disorders (5th ed.) [Citation is in section Phencyclidine Intoxication, Diagnostic Features, Criterion B]
  8. American Psychiatric Association. (2013). Substance Use Disorders. In Diagnostic and statistical manual of mental disorders (5th ed.) [Citation is in section Phencyclidine Intoxication, Diagnostic Features, Criteria B, C.1, C.6]
  9. American Psychiatric Association. (2013). Substance Use Disorders. In Diagnostic and statistical manual of mental disorders (5th ed.) [Citation is in section Phencyclidine Intoxication, Diagnostic Features, Criteria C.3, C.4, C.5]
  10. Luscher C : Drugs of abuse, in Basic and Clinical Pharmacology, 13th Edition. Edited by Katzung BG , Masters SB , Trevor AJ . Chicago, IL, McGraw-Hill Medical, 2015. [Citation is on p.16, paragraph Ketamine and Phencyclidine (PCP)]
  11. Newcomer, J. W., Farber, N. B., Jevtovic-Todorovic, V., Selke, G., Melson, A. K., Hershey, T., … & Olney, J. W. (1999). Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology, 20(2), 106-118. [Citation is on p.1-2, paragraph 2]
  12. Luisada, P. V. (1978). The Phencyclidine Psychosis: Phenomenology and Treatment. PCP, 241. [Citation is on p.242, section Definition, paragraph 1]
  13. NIDA. 2015. Hallucinogens and Dissociative Drugs: What Are the Effects of Common Dissociative Drugs on the Brain and Body? Available at https://www.drugabuse.gov/publications/research-reports/hallucinogens-dissociative-drugs/what-are-effects-common-dissociative-drugs-brain-body. Accessed 12/8/16. [Citation is in section What Are the Long-Term Effects of Dissociative Drugs?, paragraph 1]
  14. NIDA. 2006. MDMA (Ecstasy) Abuse: Letter from the Director. Available at https://www.drugabuse.gov/publications/research-reports/mdma-ecstasy-abuse/letter-director. Accessed 12/9/16. [Citation is in paragraph 1]
  15. Kalant, H. (2001). The pharmacology and toxicology of “ecstasy” (MDMA) and related drugs. Canadian Medical Association Journal, 165(7), 917-928. [Citation is on p.4, paragraph 3]
  16. Kalant, H. (2001). The pharmacology and toxicology of “ecstasy” (MDMA) and related drugs. Canadian Medical Association Journal, 165(7), 917-928. [Citation is on p.4, paragraph 2]
  17. Kalant, H. (2001). The pharmacology and toxicology of “ecstasy” (MDMA) and related drugs. Canadian Medical Association Journal, 165(7), 917-928. [Citation is on p.4, paragraph 4]
  18. Kalant, H. (2001). The pharmacology and toxicology of “ecstasy” (MDMA) and related drugs. Canadian Medical Association Journal, 165(7), 917-928. [Citation is on p.4, paragraph 5]
  19. Kalant, H. (2001). The pharmacology and toxicology of “ecstasy” (MDMA) and related drugs. Canadian Medical Association Journal, 165(7), 917-928. [Citation is on p.4, paragraph 5]
  20. Kalant, H. (2001). The pharmacology and toxicology of “ecstasy” (MDMA) and related drugs. Canadian Medical Association Journal, 165(7), 917-928. [Citation is on p.4, section Serotonin Neurotoxicity, paragraph 2]
  21. Kalant, H. (2001). The pharmacology and toxicology of “ecstasy” (MDMA) and related drugs. Canadian Medical Association Journal, 165(7), 917-928. [Citation is on p.5, paragraph 4]
  22. Kalant, H. (2001). The pharmacology and toxicology of “ecstasy” (MDMA) and related drugs. Canadian Medical Association Journal, 165(7), 917-928. [Citation is on p.5, section Long Term Psychiatric problems, paragraph 1, bullets 1,2]
  23. Kalant, H. (2001). The pharmacology and toxicology of “ecstasy” (MDMA) and related drugs. Canadian Medical Association Journal, 165(7), 917-928. [Citation is on p.5, section Long Term Psychiatric problems, paragraph 1, bullets 3,4,6]
  24. Kalant, H. (2001). The pharmacology and toxicology of “ecstasy” (MDMA) and related drugs. Canadian Medical Association Journal, 165(7), 917-928. [Citation is on p.5, section Long Term Psychiatric problems, paragraph 1, bullets 5]
  25. NIDA. 2015. Hallucinogens and Dissociative Drugs: How Do Hallucinogens (LSD, Psilocybin, Peyote, DMT, and Ayahuasca) Affect the Brain and Body? Available at https://www.drugabuse.gov/publications/research-reports/hallucinogens-dissociative-drugs/where-can-i-get-more-scientific-information-hallucinogens-diss. Accessed 12/11/16. [Citation is on paragraphs 1,2]
  26. NIDA. 2015. Hallucinogens and Dissociative Drugs: How Do Hallucinogens (LSD, Psilocybin, Peyote, DMT, and Ayahuasca) Affect the Brain and Body? Available at https://www.drugabuse.gov/publications/research-reports/hallucinogens-dissociative-drugs/where-can-i-get-more-scientific-information-hallucinogens-diss. Accessed 12/11/16. [Citation is on paragraphs 1,2]
  27. NIDA. 2015. Hallucinogens and Dissociative Drugs: How Do Hallucinogens (LSD, Psilocybin, Peyote, DMT, and Ayahuasca) Affect the Brain and Body? Available at https://www.drugabuse.gov/publications/research-reports/hallucinogens-dissociative-drugs/where-can-i-get-more-scientific-information-hallucinogens-diss. Accessed 12/11/16. [Citation is on sections LSD, Psilocybin, Peyote, DMT, and Ayahuasca]
  28. NIDA. 2015. Hallucinogens and Dissociative Drugs: How Do Hallucinogens (LSD, Psilocybin, Peyote, DMT, and Ayahuasca) Affect the Brain and Body? Available at https://www.drugabuse.gov/publications/research-reports/hallucinogens-dissociative-drugs/where-can-i-get-more-scientific-information-hallucinogens-diss. Accessed 12/11/16. [Citation is on section Short-Term General Effects of Hallucinogens, subsection Sensory Effects]
  29. Parish, BS. 2015. Hallucinogen Use: Overview Available at http://emedicine.medscape.com/article/293752-overview#showall. Accessed 12/11/16. [Citation is on section Indolealkyamines, paragraph 2]
  30. NIDA. 2015. Hallucinogens and Dissociative Drugs: How Do Hallucinogens (LSD, Psilocybin, Peyote, DMT, and Ayahuasca) Affect the Brain and Body? Available at https://www.drugabuse.gov/publications/research-reports/hallucinogens-dissociative-drugs/where-can-i-get-more-scientific-information-hallucinogens-diss. Accessed 12/11/16. [Citation is on section Long-Term Effects of Hallucinogens, subsections Persistent psychosis and Hallucinogen Persisting Perception Disorder]
  31. NIDA. 2015. Hallucinogens and Dissociative Drugs: How Do Hallucinogens (LSD, Psilocybin, Peyote, DMT, and Ayahuasca) Affect the Brain and Body? Available at https://www.drugabuse.gov/publications/research-reports/hallucinogens-dissociative-drugs/where-can-i-get-more-scientific-information-hallucinogens-diss. Accessed 12/11/16. [Citation is on section Long-Term Effects of Hallucinogens, subsections Persistent psychosis]
  32. NIDA. 2015. Hallucinogens and Dissociative Drugs: How Do Hallucinogens (LSD, Psilocybin, Peyote, DMT, and Ayahuasca) Affect the Brain and Body? Available at https://www.drugabuse.gov/publications/research-reports/hallucinogens-dissociative-drugs/where-can-i-get-more-scientific-information-hallucinogens-diss. Accessed 12/11/16. [Citation is on section Long-Term Effects of Hallucinogens, subsections Hallucinogen Persisting Perception Disorder]
  33. Rickert, V. I., Siqueira, L. M., Dale, T., & Wiemann, C. M. (2003). Prevalence and risk factors for LSD use among young women. Journal of pediatric and adolescent gynecology, 16(2), 67-75. [Citation is on p.1, paragraph 1]
  34. NIDA. 2015. Hallucinogens and Dissociative Drugs: Brief Description. Available at https://www.drugabuse.gov/publications/research-reports/hallucinogens-dissociative-drugs/director. Accessed 12/8/16. [Citation is in paragraph 2]
  35. Stone, A. L., O’Brien, M. S., De La Torre, A., & Anthony, J. C. (2007). Who is becoming hallucinogen dependent soon after hallucinogen use starts?. Drug and alcohol dependence, 87(2), 153-163. [Citation is on p.11, section Discussion, paragraph 1]
  36. McCambridge, J., Winstock, A., Hunt, N., & Mitcheson, L. (2006). 5-Year trends in use of hallucinogens and other adjunct drugs among UK dance drug users. European addiction research, 13(1), 57-64. [Citation is on p.1, section Introduction, paragraph 1]
  37. Wu, L. T., Ringwalt, C. L., Mannelli, P., & Patkar, A. A. (2008). Hallucinogen use disorders among adult users of MDMA and other hallucinogens. American Journal on Addictions, 17(5), 354-363. [Citation is on p.7, section Discussion, paragraph 1]
  38. Wu, L. T., Ringwalt, C. L., Mannelli, P., & Patkar, A. A. (2008). Hallucinogen use disorders among adult users of MDMA and other hallucinogens. American Journal on Addictions, 17(5), 354-363. [Citation is on p.7, section Discussion, paragraph 1]
  39. NIDA. 2014. Hallucinogen: Brief Description. Available at https://www.drugabuse.gov/drugs-abuse/hallucinogens. Accessed 12/8/16. [Citation is on table National Survey on Drug Use and Health: Trends in Prevalence of Various Drugs for Ages 12 or Older, Ages 12 to 17, Ages 18 to 25, and Ages 26 or Older; 2015]
  40. NIDA. 2013. MDMA: Brief Description. Available at https://www.drugabuse.gov/drugs-abuse/mdma-ecstasymolly. Accessed 12/8/16. [Citation is on table National Survey on Drug Use and Health: Trends in Prevalence of MDMA for Ages 12 or Older, Ages 12 to 17, Ages 18 to 25, and Ages 26 or Older; 2015]
  41. Wu, L. T., Schlenger, W. E., & Galvin, D. M. (2006). Concurrent use of methamphetamine, MDMA, LSD, ketamine, GHB, and flunitrazepam among American youths. Drug and alcohol dependence, 84(1), 102-113. [Citation is on p.3, paragraph 3]
  42. NIDA. 2014. Hallucinogen: Brief Description. Available at https://www.drugabuse.gov/drugs-abuse/hallucinogens. Accessed 12/8/16. [Citation is on table National Survey on Drug Use and Health: Trends in Prevalence of Various Drugs for Ages 12 or Older, Ages 12 to 17, Ages 18 to 25, and Ages 26 or Older; 2015]
  43. NIDA. 2016. Marijuana: Brief Description. Available at https://www.drugabuse.gov/drugs-abuse/marijuana. Accessed 12/8/16. [Citation is on table National Survey on Drug Use and Health: Trends in Prevalence of Marijuana/ Hashish for Ages 12 or Older, Ages 12 to 17, Ages 18 to 25, and Ages 26 or Older; 2015]
  44. NIDA. 2016. Alcohol: Brief Description. Available at https://www.drugabuse.gov/drugs-abuse/alcohol. Accessed 12/8/16. [Citation is on table National Survey on Drug Use and Health: Trends in Prevalence of Alcohol for Ages 12 or Older, Ages 12 to 17, Ages 18 to 25, and Ages 26 or Older; 2015]
  45. NIDA. 2013. MDMA: Brief Description. Available at https://www.drugabuse.gov/drugs-abuse/mdma-ecstasymolly. Accessed 12/8/16. [Citation is on table National Survey on Drug Use and Health: Trends in Prevalence of MDMA for Ages 12 or Older, Ages 12 to 17, Ages 18 to 25, and Ages 26 or Older; 2015]
  46. Stone, A. L., O’Brien, M. S., De La Torre, A., & Anthony, J. C. (2007). Who is becoming hallucinogen dependent soon after hallucinogen use starts?. Drug and alcohol dependence, 87(2), 153-163. [Citation is on p.11, section Discussion, paragraph 1]
  47. Kalant, H. (2001). The pharmacology and toxicology of “ecstasy” (MDMA) and related drugs. Canadian Medical Association Journal, 165(7), 917-928. [Citation is on p.8, section Addiction, paragraph 2]
  48. Luscher C : Drugs of abuse, in Basic and Clinical Pharmacology, 13th Edition. Edited by Katzung BG , Masters SB , Trevor AJ . Chicago, IL, McGraw-Hill Medical, 2015. [Citation is on p.9, paragraph 1]
  49. Schuster, P., Lieb, R., Lamertz, C., & Wittchen, H. U. (1998). Is the use of ecstasy and hallucinogens increasing?. European addiction research, 4(1-2), 75-82. [Citation is on p.7, paragraph 3]
  50. Wu, L. T., Ringwalt, C. L., Mannelli, P., & Patkar, A. A. (2008). Hallucinogen use disorders among adult users of MDMA and other hallucinogens. American Journal on Addictions, 17(5), 354-363. [Citation is on p.7, section Discussion, paragraph 2]
  51. Schuster, P., Lieb, R., Lamertz, C., & Wittchen, H. U. (1998). Is the use of ecstasy and hallucinogens increasing?. European addiction research, 4(1-2), 75-82. [Citation is on p.7, paragraph 4]
  52. Schuster, P., Lieb, R., Lamertz, C., & Wittchen, H. U. (1998). Is the use of ecstasy and hallucinogens increasing?. European addiction research, 4(1-2), 75-82. [Citation is on p.7, paragraph 2]
  53. Wu, L. T., Schlenger, W. E., & Galvin, D. M. (2006). Concurrent use of methamphetamine, MDMA, LSD, ketamine, GHB, and flunitrazepam among American youths. Drug and alcohol dependence, 84(1), 102-113. [Citation is on p.1, section Introduction, paragraph 1]
  54. Wu, L. T., Ringwalt, C. L., Mannelli, P., & Patkar, A. A. (2008). Hallucinogen use disorders among adult users of MDMA and other hallucinogens. American Journal on Addictions, 17(5), 354-363. [Citation is on p.7, section Discussion, paragraph 2]
  55. Huizink, A. C., Ferdinand, R. F., van der Ende, J., & Verhulst, F. C. (2006). Symptoms of anxiety and depression in childhood and use of MDMA: prospective, population based study. Bmj, 332(7545), 825-828. [Citation is on p.4, section Discussion]
  56. Rickert, V. I., Siqueira, L. M., Dale, T., & Wiemann, C. M. (2003). Prevalence and risk factors for LSD use among young women. Journal of pediatric and adolescent gynecology, 16(2), 67-75. [Citation is in p.6, section DIscussion, paragraph 2]
  57. Rickert, V. I., Siqueira, L. M., Dale, T., & Wiemann, C. M. (2003). Prevalence and risk factors for LSD use among young women. Journal of pediatric and adolescent gynecology, 16(2), 67-75. [Citation is in p.7, paragraph 2]
  58. American Psychiatric Association. (2013). Substance Use Disorders. In Diagnostic and statistical manual of mental disorders (5th ed.) [Citation is in section Phencyclidine Use Disorder, Diagnostic Features, paragraph 1]
  59. American Psychiatric Association. (2013). Substance Use Disorders. In Diagnostic and statistical manual of mental disorders (5th ed.) [Citation is in section Other Hallucinogen Use Disorder, Diagnostic Features, paragraph 1]
  60. American Psychiatric Association. (2013). Substance Use Disorders. In Diagnostic and statistical manual of mental disorders (5th ed.) [Citation is in section Other Hallucinogen Use Disorder, Diagnostic Features, paragraph 1]
  61. Center for Substance Abuse Research. 2013. LSD. Available at http://www.cesar.umd.edu/cesar/drugs/lsd.asp. Accessed on 12/6/16. [Citation is on section History, paragraph 1]
  62. Center for Substance Abuse Research. 2013. Ecstasy. Available at http://www.cesar.umd.edu/cesar/drugs/ecstasy.asp. Accessed on 12/6/16. [Citation is on section History, paragraph 1]
  63. NIDA. 2006. What is MDMA? Available at https://www.drugabuse.gov/publications/research-reports/mdma-ecstasy-abuse/what-mdma. Accessed 12/6/16. [Citation is on paragraph 1]
  64. Center for Substance Abuse Research. 2013. LSD. Available at http://www.cesar.umd.edu/cesar/drugs/lsd.asp. Accessed on 12/6/16. [Citation is on section Profile, paragraph 1]
  65. Center for Substance Abuse Research. 2013. Peyote. Available at http://www.cesar.umd.edu/cesar/drugs/peyote.asp. Accessed on 12/6/16. [Citation is on section Profile, paragraph 1]
  66. American Psychiatric Association. (2013). Substance Use Disorders. In Diagnostic and statistical manual of mental disorders (5th ed.) [Citation is in section Other Hallucinogen Use Disorder, Diagnostic Features, paragraph 1]
  67. American Psychiatric Association. (2013). Substance Use Disorders. In Diagnostic and statistical manual of mental disorders (5th ed.) [Citation is in section Other Hallucinogen Use Disorder, Diagnostic Features, paragraph 2]
  68. American Psychiatric Association. (2013). Substance Use Disorders. In Diagnostic and statistical manual of mental disorders (5th ed.) [Citation is in section Other Hallucinogen Use Disorder, subsection Diagnostic Criteria, Criterion A]
  69. American Psychiatric Association. (2013). Substance-Related and Addictive Disorders. In Diagnostic and statistical manual of mental disorders (5th ed.). [Citation is in section Other Hallucinogen Use Disorder subsection Diagnostic Criteria]
  70. American Psychiatric Association. (2013). Substance Use Disorders. In Diagnostic and statistical manual of mental disorders (5th ed.) [Citation is in section Other Hallucinogen Use Disorder, subsection Diagnostic Criteria, Criteria A.10 ]
  71. Borke, J. (2016). Substance use – phencyclidine (PCP). Available at https://medlineplus.gov/ency/patientinstructions/000797.htm. Accessed on 12/17/16. [Citation is in section PCP can be Addictive, paragraph 1, bullets 1,2,3; section Treatment options, paragraph 2]
  72. American Psychiatric Association. (2013). Substance Use Disorders. In Diagnostic and statistical manual of mental disorders (5th ed.) [Citation is in section Other Hallucinogen Use Disorder, subsection Diagnostic Criteria, Severity Criteria]
  73. American Psychiatric Association. (2013). Substance Use Disorders. In Diagnostic and statistical manual of mental disorders (5th ed.) [Citation is in section Other Hallucinogen Use Disorder, subsection Diagnostic Criteria, Remission Criteria]
  74. American Psychiatric Association. (2013). Substance Use Disorders. In Diagnostic and statistical manual of mental disorders (5th ed.) [Citation is in section Other Hallucinogen Use Disorder, subsection Diagnostic Criteria, Remission Criteria]
  75. NIDA. 2006. Are there effective treatments for MDMA abuse? Available at https://www.drugabuse.gov/publications/research-reports/mdma-ecstasy-abuse/are-there-effective-treatments-mdma-abuse. Accessed 12/7/16. [Citation is in paragraph 1]
  76. American Psychiatric Association. (2013). Substance Use Disorders. In Diagnostic and statistical manual of mental disorders (5th ed.) [Citation is in section Phencyclidine Use Disorder, Diagnostic Features, paragraph 1]
  77. American Psychiatric Association. (2013). Substance Use Disorders. In Diagnostic and statistical manual of mental disorders (5th ed.) [Citation is in section Hallucinogen Persisting Perception Disorder, Diagnostic Features, paragraph 1]
  78. American Psychiatric Association. (2013). Substance Use Disorders. In Diagnostic and statistical manual of mental disorders (5th ed.) [Citation is in section Hallucinogen Persisting Perception Disorder, Diagnostic Features, paragraph 2]
  79. Espiard, M. L., Lecardeur, L., Abadie, P., Halbecq, I., & Dollfus, S. (2005). Hallucinogen persisting perception disorder after psilocybin consumption: a case study. European psychiatry, 20(5), 458-460. [Citation is on p.1, paragraph 2]
  80. Halpern, J. H., & Pope, H. G. (2003). Hallucinogen persisting perception disorder: what do we know after 50 years?. Drug and alcohol dependence, 69(2), 109-119. [Citation is on p.8, section Treatment, paragraph 1]
  81. Hermle, L., Simon, M., Ruchsow, M., & Geppert, M. (2012). Hallucinogen-persisting perception disorder. Therapeutic Advances in Psychopharmacology, 2(5), 199–205. [Citation is on p.4, section DIscussion, paragraph 1]
  82. Hermle, L., Simon, M., Ruchsow, M., & Geppert, M. (2012). Hallucinogen-persisting perception disorder. Therapeutic Advances in Psychopharmacology, 2(5), 199–205. [Citation is on p.4, section DIscussion, paragraph 5]
  83. Halpern, J. H., & Pope, H. G. (2003). Hallucinogen persisting perception disorder: what do we know after 50 years?. Drug and alcohol dependence, 69(2), 109-119. [Citation is on p.9, Table 2]
  84. Abraham, H. D., & Mamen, A. (1996). LSD-like panic from risperidone in post-LSD visual disorder. Journal of clinical psychopharmacology, 16(3), 238-241. [Citation is on p.3, section DIscussion, paragraphs 1,2]
  85. Espiard, M. L., Lecardeur, L., Abadie, P., Halbecq, I., & Dollfus, S. (2005). Hallucinogen persisting perception disorder after psilocybin consumption: a case study. European psychiatry, 20(5), 458-460. [Citation is on p.2, paragraph 4]
  86. NIDA. 2015. Hallucinogens and Dissociative Drugs: How Do Hallucinogens (LSD, Psilocybin, Peyote, DMT, and Ayahuasca) Affect the Brain and Body? Available at https://www.drugabuse.gov/publications/research-reports/hallucinogens-dissociative-drugs/where-can-i-get-more-scientific-information-hallucinogens-diss. Accessed 12/19/16. [Citation is on section What are the Long-Term Effects of Hallucinogens?, paragraph 5]
  87. American Psychiatric Association. (2013). Substance Use Disorders. In Diagnostic and statistical manual of mental disorders (5th ed.) [Citation is in section Phencyclidine Intoxication, Diagnostic Criteria, Criterion B]
  88. Brenner, Stephan. (2014). PCP Toxicity Treatment and Management. Available at http://emedicine.medscape.com/article/1010821-treatment?pa=tON6JSbIj6h0fSibd%2FLBTNjjQjwlVLMQ1n09w57CpWQ%2BIwkQYp5AxPnqeBX5Ivurd%2FsGPYa%2BToEoLjuhFnUEHw%3D%3D#showall. Accessed 12/17/16. [Citation is on paragraph 5, 8]
  89. Bey, T., & Patel, A. (2007). Phencyclidine intoxication and adverse effects: a clinical and pharmacological review of an illicit drug. The California Journal of Emergency Medicine, 8(1), 9. [Citation is on p.4, section Management, paragraph 2]
  90. Bey, T., & Patel, A. (2007). Phencyclidine intoxication and adverse effects: a clinical and pharmacological review of an illicit drug. The California Journal of Emergency Medicine, 8(1), 9. [Citation is on p.2, section Clinical Manifestations, paragraph 5]
  91. Luisada, P. V. (1978). The Phencyclidine Psychosis: Phenomenology and Treatment. PCP, 241. [Citation is on p.250, paragraph 3; p.255, paragraph 1; p.256, paragraph 1; p. 257, paragraph 5]
  92. Parrott, A. C. (2001). Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research. Human Psychopharmacology: Clinical and Experimental, 16(8), 557-577. [Citation is on p.13, paragraph 1]
  93. Hall, A. P., & Henry, J. A. (2006). Acute toxic effects of ‘Ecstasy’(MDMA) and related compounds: overview of pathophysiology and clinical management. British journal of anaesthesia, 96(6), 678-685. [Citation is on p.6, paragraph 2]
  94. Pallanti, S., & Mazzi, D. (1992). MDMA (Ecstasy) precipitation of panic disorder. Biological psychiatry, 32(1), 91-95. [Citation is on p.1, paragraph 4]
  95. Hall, A. P., & Henry, J. A. (2006). Acute toxic effects of ‘Ecstasy’(MDMA) and related compounds: overview of pathophysiology and clinical management. British journal of anaesthesia, 96(6), 678-685. [Citation is on p.6, paragraph 2]
  96. Parrott, A. C. (2001). Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research. Human Psychopharmacology: Clinical and Experimental, 16(8), 557-577. [Citation is on p.6, paragraph 1]
  97. Parrott, A. C. (2001). Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research. Human Psychopharmacology: Clinical and Experimental, 16(8), 557-577. [Citation is on p.6, paragraph 1]
  98. Parrott, A. C. (2001). Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research. Human Psychopharmacology: Clinical and Experimental, 16(8), 557-577. [Citation is on p.5, paragraph 4]
  99. Parrott, A. C. (2001). Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research. Human Psychopharmacology: Clinical and Experimental, 16(8), 557-577. [Citation is on p.6, paragraph 2, 3]
  100. Bey, T., & Patel, A. (2007). Phencyclidine intoxication and adverse effects: a clinical and pharmacological review of an illicit drug. The California Journal of Emergency Medicine, 8(1), 9. [Citation is on p.4, section Management, paragraph 2]
  101. NIDA for Teens. (2015). Concerts and Drugs: Is There a Way to Reduce the Dangers? Available at https://teens.drugabuse.gov/blog/post/concerts-and-drugs-there-way-reduce-dangers. Accessed 12/19/2016. [Citation is on section Lightning in a Bottle, paragraph 1]
  102. DanceSafe. (2016). Heatstroke. Available at https://dancesafe.org/heatstroke/. Accessed on 12/19/2016. [Citation is on section How to Prevent Heat Stroke, paragraph 1]
  103. DanceSafe. (2016). Drug Checking. Available at https://dancesafe.org/drug-checking/. Accessed on 12/19/2016. [Citation is on section Onsite Pill Testing, paragraph 1]
  104. Bey, T., & Patel, A. (2007). Phencyclidine intoxication and adverse effects: a clinical and pharmacological review of an illicit drug. The California Journal of Emergency Medicine, 8(1), 9. [Citation is on p.2, section Clinical Manifestations, paragraph 3]
  105. Luisada, P. V. (1978). The Phencyclidine Psychosis: Phenomenology and Treatment. PCP, 241. [Citation is on p.255, paragraph 1]
  106. American Psychiatric Association. (2013). Substance Use Disorders. In Diagnostic and statistical manual of mental disorders (5th ed.) [Citation is in section Other Hallucinogen Use Disorder, Differential Diagnosis, subsection Schizophrenia]
  107. NIDA. 2015. Hallucinogens and Dissociative Drugs: How Do Hallucinogens (LSD, Psilocybin, Peyote, DMT, and Ayahuasca) Affect the Brain and Body? Available at https://www.drugabuse.gov/publications/research-reports/hallucinogens-dissociative-drugs/where-can-i-get-more-scientific-information-hallucinogens-diss. Accessed 12/19/16. [Citation is on section What are the Short-Term Effects of Hallucinogens?, paragraph 1]
  108. DanceSafe. (2016). LSD. Available at https://dancesafe.org/lsd/. Accessed 12/19/2016. [Citation is on section What if somebody is having a bad trip?]